Category
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Today's News
More News
After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v
Crown Hair Transplants

Crown Hair Transplants

The crown region of a patient’s scalp has, for many years, been considered the “taboo” region for surgical intervention. This is due to several reasons. The first of which is that even the most effici

Crown Hair Transplants

The crown region of a patient’s scalp has, for many years, been considered the “taboo” region for surgical intervention. This is due to several reasons. The first of which is that even the most effici
Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients
MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9, 2021Darlene Dobkowski, MAFor patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease m

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9, 2021Darlene Dobkowski, MAFor patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease m
Female Hair Restoration

Female Hair Restoration

Key pointsFemale hair loss is a prevalent condition with a particularly devastating psychological impact.Hair transplantation is the only currently available option to provide a permanent and natural

Female Hair Restoration

Key pointsFemale hair loss is a prevalent condition with a particularly devastating psychological impact.Hair transplantation is the only currently available option to provide a permanent and natural
Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25, 2022Lindsay FischerPatients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.Effective methods of m

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25, 2022Lindsay FischerPatients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.Effective methods of m
Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

August 27, 2022Lisa AstorRelapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.Multiple Mye

Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

August 27, 2022Lisa AstorRelapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.Multiple Mye
Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm
Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na
With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10, 2021Kristi RosaPatients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood o

With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10, 2021Kristi RosaPatients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood o
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...